``

Gujarat Kidney IPO Analyzed

The Gujarat Kidney and Super Speciality IPO was a big success. Investors showed strong interest, bidding for 6.89 crore shares when the company only offered 1.32 crore. This means the issue was subscribed 5.21 times – that’s a lot of people wanting to buy in! The IPO will finish on December 24th, 2025, and the price for each share is between Rs 108 and Rs 114.

Key Points

• IPO subscribed 5.21 times, exceeding initial offer.
• Raised Rs 100.01 crore from anchor investors.
• Funds used for hospitals, equipment, and debt repayment.
• Promoters own 99.1% of the company pre-IPO.
• Company provides multispeciality healthcare services in Gujarat.
• Net profit of Rs 4.84 crore for the period ending June 2025.

The company plans to use the money it raised to buy a new hospital in Ahmedabad, upgrade medical equipment, and pay back some debts. It’s also investing in new technology for its hospitals. The IPO itself raised a good amount of money – Rs 100.01 crore – thanks to help from big investors called ‘anchor investors’ who bought shares ahead of time.

Gujarat Kidney specializes in providing care for many different health problems. They have seven hospitals and four pharmacies. They treat a wide range of illnesses, including kidney problems, heart problems, and surgeries. Their biggest income comes from people who pay directly for their care, not from the government.

Specifically, they earn money from government groups (5.46%), insurance companies (13.9%), and directly from patients (80.64%). For the first three months of the next year (Q1 FY2026), the company made a profit of Rs 4.84 crore and earned Rs 15.26 crore in revenue.

The IPO’s strong performance indicates confidence in the company’s future growth and expansion plans.

`